Clinical Trials · NCT03012594
Lanreotide in the Treatment of Small Bowel Motility Disorders
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Northwell Health
- Enrollment
- 12
- Start date
- May 2017
- Locations
- 2 sites, United States
- Primary endpoint
- Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill